A Review of the Progress and Challenges of Developing a Vaccine for COVID-19

Omna Sharma, Ali A Sultan, Hong Ding, Chris R Triggle, Omna Sharma, Ali A Sultan, Hong Ding, Chris R Triggle

Abstract

A novel coronavirus, which has been designated as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first detected in December 2019 in Wuhan China and causes the highly infectious disease referred to as COVID-19. COVID-19 has now spread worldwide to become a global pandemic affecting over 24 million people as of August 26th, 2020 and claimed the life of more than 800,000 people worldwide. COVID-19 is asymptomatic for some individuals and for others it can cause symptoms ranging from flu-like to acute respiratory distress syndrome (ARDS), pneumonia and death. Although it is anticipated that an effective vaccine will be available to protect against COVID-19, at present the world is relying on social distancing and hygiene measures and repurposed drugs. There is a worldwide effort to develop an effective vaccine against SARS-CoV-2 and, as of late August 2020, there are 30 vaccines in clinical trials with over 200 in various stages of development. This review will focus on the eight vaccine candidates that entered Phase 1 clinical trials in mid-May, including AstraZeneca/Oxford's AZD1222, Moderna's mRNA-1273 and Sinovac's CoronaVac vaccines, which are currently in advanced stages of vaccine development. In addition to reviewing the different stages of vaccine development, vaccine platforms and vaccine candidates, this review also discusses the biological and immunological basis required of a SARS-CoV-2 vaccine, the importance of a collaborative international effort, the ethical implications of vaccine development, the efficacy needed for an immunogenic vaccine, vaccine coverage, the potential limitations and challenges of vaccine development. Although the demand for a vaccine far surpasses the production capacity, it will be beneficial to have a limited number of vaccines available for the more vulnerable population by the end of 2020 and for the rest of the global population by the end of 2021.

Keywords: COVID-19 pandemic; DNA vaccine; RNA vaccine; SARS-CoV-2; inactivated virus particle vaccine; neutralizing antibodies; non-replication viral vector vaccine; vaccine development.

Copyright © 2020 Sharma, Sultan, Ding and Triggle.

Figures

Figure 1
Figure 1
Flowchart showing traditional process of vaccine development from exploratory, pre-clinical studies to Phase 1 studies in a comparatively few control volunteers as depicted by the figure to larger Phase 2 and Phase 3 studies. The symbol is a representation of the number of human subjects in trials.
Figure 2
Figure 2
Flowchart showing accelerated process of vaccine development in a pandemic with combined phases, pre-approval, and rapid large-scale manufacturing. The symbol is a representation of the number of human subjects in trials.
Figure 3
Figure 3
Schematic showing a representation of SARS-CoV-2 along with different components of the virus as potential vaccine targets. SARS-CoV-2 is a single stranded RNA virus, has a lipid bilayer and consists of a spike S protein along with membrane and envelope proteins. DNA and RNA-based vaccines are made from the viral sequence of the virus. Viral vector vaccines utilize another virus, for example an adenovirus, and incorporate genetic material from SARS-CoV-2 into its genome. Inactivated vaccines involve SARS-CoV-2 that has been killed using physical or chemical means.

References

    1. Randolph HE, Barreiro LB. Herd immunity: understanding COVID-19. Immunity. (2020) 52:737–41. 10.1016/j.immuni.2020.04.012
    1. Jung F, Krieger V, Hufert FT, Kupper JH. Herd immunity or suppression strategy to combat COVID-19. Clin Hemorheol Microcirc. (2020) 75:13–7. 10.3233/CH-209006
    1. Sempowski GD, Saunders KO, Acharya P, Wiehe KJ, Haynes BF. Pandemic preparedness: developing vaccines and therapeutic antibodies for COVID-19. Cell. (2020) 181:1458–63. 10.1016/j.cell.2020.05.041
    1. Yu F, Du L, Ojcius DM, Pan C, Jiang S. Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China. Microbes Infect. (2020) 22:74–9. 10.1016/j.micinf.2020.01.003
    1. Tang D, Comish P, Kang R. The hallmarks of COVID-19 disease. PLoS Pathog. (2020) 16:e1008536. 10.1371/journal.ppat.1008536
    1. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nat Med. (2020) 26:450–2. 10.1038/s41591-020-0820-9
    1. Han HJ, Wen HL, Zhou CM, Chen FF, Luo LM, Liu JW, et al. . Bats as reservoirs of severe emerging infectious diseases. Virus Res. (2015) 205:1–6. 10.1016/j.virusres.2015.05.006
    1. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutierrez-Ocampo E, Villamizar-Pena R, Holguin-Rivera Y, Escalera-Antezana JP, et al. . Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis. (2020) 34:101623. 10.1016/j.tmaid.2020.101623
    1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. (2020) 395:497–506. 10.1016/S0140-6736(20)30183-5
    1. Tse LV, Meganck RM, Graham RL, Baric RS. The current and future state of vaccines, antivirals and gene therapies against emerging coronaviruses. Front Microbiol. (2020) 11:658. 10.3389/fmicb.2020.00658
    1. Graham BS. Rapid COVID-19 vaccine development. Science. (2020) 368:945–6. 10.1126/science.abb8923
    1. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. . Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. (2020) 367:1260–3. 10.1126/science.abb2507
    1. Roossinck MJ. The Mysterious Disappearance of the First SARS Virus, and Why we need a Vaccine for the Current One But Didn't for the Other. (2020). Available online at: (accessed June 25, 2020).
    1. Liu Y, Gayle AA, Wilder-Smith A, Rocklöv J. The reproductive number of COVID-19 is higher compared to SARS coronavirus. J Travel Med. (2020) 27:1–4. 10.1093/jtm/taaa021
    1. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. . Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. (2020) 181:1489–501.e15. 10.1016/j.cell.2020.05.015
    1. Leslie M. T Cells Found in COVID-19 Patients Bode Well for Long-Term Immunity. (2020). Available online at: (accessed June 26, 2020). 10.1126/science.abc8120
    1. Chavarria-Miró G, Anfruns-Estrada E, Guix S, Paraira M, Galofré B, Sánchez G, et al. Sentinel surveillance of SARS-CoV-2 in waste water anticipates the occurrence of COVID-19 cases. medRxiv [Preprint]. (2020). 10.1101/2020.06.13.20129627
    1. Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, et al. . SARS-CoV-2 specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. (2020) 584:457–62. 10.1038/s41586-020-2550-z
    1. Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S, et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv [Preprint]. (2020). 10.2139/ssrn.3566211
    1. Adams ER, Ainsworth M, Anand R, Andersson MI, Auckland K, Baillie JK, et al. Antibody testing for COVID-19: a report from the national COVID scientific advisory panel. medRxiv [Preprint]. (2020). 10.12688/wellcomeopenres.15927.1
    1. Vabret N, Britton GJ, Gruber C, Hegde S, Kim J, Kuksin M, et al. . Immunology of COVID-19: current state of the science. Immunity. (2020) 52:910–41. 10.1016/j.immuni.2020.05.002
    1. Liu W, Fontanet A, Zhang PH, Zhan L, Xin ZT, Baril L, et al. . Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome. J Infect Dis. (2006) 193:792–5. 10.1086/500469
    1. Callaway E. Coronavirus vaccines leap through safety trials - but which will work is anybody's guess. Nature. (2020) 583:669–70. 10.1038/d41586-020-02174-y
    1. Han S. Clinical vaccine development. Clin Exp Vaccine Res. (2015) 4:46–53. 10.7774/cevr.2015.4.1.46
    1. Singh K, Mehta S. The clinical development process for a novel preventive vaccine: an overview. J Postgrad Med. (2016) 62:4–11. 10.4103/0022-3859.173187
    1. Conforti A, Marra E, Roscilli G, Palombo F, Ciliberto G, Aurisicchio L. Are genetic vaccines the right weapon against COVID-19? Mol Ther. (2020) 28:1555–6. 10.1016/j.ymthe.2020.06.007
    1. Sharpe HR, Gilbride C, Allen E, Belij-Rammerstorfer S, Bissett C, Ewer K, et al. . The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world. Immunology. (2020) 160:223–32. 10.1111/imm.13222
    1. WHO Draft Landscape of COVID-19 Candidate Vaccines. (2020). Available online at: (accessed August 20, 2020).
    1. Corey L, Mascola JR, Fauci AS, Collins FS. A strategic approach to COVID-19 vaccine R&D. Science. (2020) 368:948–50. 10.1126/science.abc5312
    1. Lurie N, Saville M, Hatchett R, Halton J. Developing Covid-19 vaccines at pandemic speed. N Engl J Med. (2020) 382:1969–73. 10.1056/NEJMp2005630
    1. Corum J, Grady D, Wee S-L, Zimmer C. Coronavirus Vaccine Tracker. (2020). Available online at: (accessed July 14, 2020).
    1. Safety Tolerability Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19 (2020). Available online at: (accessed July 5, 2020).
    1. INOVIO Announces Positive Interim Phase 1 Data For INO-4800 Vaccine for COVID-19 (2020). Available online at: (accessed July 10, 2020).
    1. Triggle CR, Bansal D, Farag EABA, Ding H, Sultan AA. COVID-19: learning from lessons to guide treatment and prevention interventions. mSphere. (2020) 5:e00317–20. 10.1128/mSphere.00317-20
    1. Corbett KS, Edwards DK, Leist SR, Abiona OM, Boyoglu-Barnum S, Gillespie RA, et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. (2020). 10.1038/s41586-020-2622-0. [Epub ahead of print].
    1. Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. . An mRNA vaccine against SARS-CoV-2 — preliminary report. N Engl J Med. (2020) NEJMoa2022483. 10.1056/NEJMoa2022483. [Epub ahead of print].
    1. Mishra S. An Infectious Disease Expert Explains The Results from Moderna's Latest Vaccine Trials. (2020). Available online at: (accessed July 18, 2020).
    1. Dose-Confirmation Study to Evaluate the Safety Reactogenicity and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older (2020). Available online at: (accessed July 6, 2020).
    1. A Phase 3 Randomized Stratified Observer-Blind Placebo-Controlled Study to Evaluate the Efficacy Safety Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years Older. (2020). Available online at: (accessed August 18, 2020).
    1. Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart SP, et al. Phase 1/2 study to describe the safety and immunogenicity of a COVID-19 RNA vaccine candidate (BNT162b1) in adults 18 to 55 years of age: interim report. medRxiv. (2020). 10.1101/2020.06.30.20142570
    1. Studies at Pirbright Demonstrate Two Doses of Oxford University's COVID-19 Vaccine Boosts Immune Response In Pigs (2020). Available online at: (accessed July 10, 2020).
    1. A phase I/II Study to Determine Efficacy Safety Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19 in UK Healthy Adult Volunteers. (2020). Available online at: (accessed July 7, 2020).
    1. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. . Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized control trial. Lancet. (2020) 396:467–78. 10.1016/S0140-6736(20)31604-4
    1. COVID-19 Vaccine (ChAdOx1 nCoV-19) trial in South African Adults with without HIV-Infection. (2020). Available online at: (accessed July 7, 2020).
    1. A Phase 2/3 Study to Determine the Efficacy Safety Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19. (2020). Available online at: (accessed July 7, 2020).
    1. A Phase III Study to Investigate a Vaccine Against COVID-19. (2020). Available online at: (accessed August 20, 2020).
    1. A Phase III Randomized Double-blind Placebo-controlled Multicenter Study in Adults to Determine the Safety Efficacy and Immunogenicity of AZD1222 a Non-replicating ChAdOx1 Vector Vaccine for the Prevention of COVID-19 (2020). Available online at: (accessed August 20, 2020).
    1. Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, et al. . Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomized, first-in-human trial. Lancet. (2020) 395:1845–54. 10.1016/S0140-6736(20)31208-3
    1. Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, et al. . Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomized, double-blind, placebo-controlled, phase 2 trial. Lancet. (2020) 396:479–88. 10.1016/S0140-6736(20)31605-6
    1. CanSino's COVID-19 Vaccine Candidate Approved for Military use in China. (2020). Available online at: (accessed August 19, 2020).
    1. CanSino Biologics Breakthrough: Saudi Arabia to Proceed on Phase 3 Trial. (2020). Available online at: (accessed August 19, 2020).
    1. Sumner M. Why One Vaccine is Already a Sure Loser, and also a Sure Winner, in the Race to Inoculate the World. (2020). Available online at: (accessed July 27, 2020).
    1. Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, et al. . Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes. JAMA. (2020) 324:951–60. 10.1001/jama.2020.15543
    1. Wang H, Zhang Y, Huang B, Deng W, Quan Y, Wang W, et al. . Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell. (2020) 182:713–21. 10.1016/j.cell.2020.06.008
    1. A Randomized Double-Blind Placebo Parallel-Controlled Phase I/II Clinical Trial for Inactivated Novel Coronavirus Pneumonia Vaccine (Vero cells) (2020). Available online at: (accessed July 10, 2020).
    1. Sinopharm Says Second Covid Vaccine Found to Be Safe. (2020). Available online at: (accessed July 10, 2020).
    1. Chinese COVID-19 Vaccine Candidate the First to Start Phase 3 Clinical Trials Worldwide. (2020). Available online at: (accessed July 10, 2020).
    1. Double-Blind Randomized Placebo-Controlled Phase III Clinical Trial to Evaluate Efficacy and Safety in Healthcare Professionals of the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac (2020). Available online at: (accessed August 21, 2020).
    1. Indonesia Testing Location for China's Sinovac Phase 3 Clinical Trial. (2020). Available online at: (accessed August 18, 2020).
    1. Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, et al. . Development of an inactivated vaccine candidate for SARS-CoV-2. Science. (2020) 369:77–81. 10.1126/science.abc1932
    1. Feuerstein A. Sinovac Says Early Data Show its Covid-19 Vaccine Generated Immune Responses. (2020). Available online at: (accessed August 21, 2020).
    1. Zhang Y, Zeng G, Pan H, Li C, Kan B, Hu Y, et al. Immunogenicity and Safety of a SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: report of the randomized, double-blind, and placebo-controlled Phase 2 clinical trial. medRxiv [Preprint]. (2020). 10.1101/2020.07.31.20161216
    1. Gavi the Vaccine Alliance. Available online at: (accessed July 4, 2020).
    1. Gates Foundation Expands Commitment to COVID-19 Response Calls for International Collaboration. (2020). Available online at: (accessed July 4, 2020).
    1. CEPI - COVID-19,. (2020). Available online at: (accessed July 10, 2020).
    1. WHO Coronavirus Disease (COVID-19). (2020). Available online at: (accessed July 10, 2020)
    1. McCarthy T. Fear Mounts Trump May Pressure FDA to Rush Covid-19 Vaccine by Election. (2020) Available online at: (accessed June 26, 2020).
    1. Jiang S. Don't rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees. Nature. (2020) 579:321. 10.1038/d41586-020-00751-9
    1. Callaway E. Russia's fast track coronavirus vaccine draws outrage over safety. Nature. (2020) 584:334–5. 10.1038/d41586-020-02386-2
    1. Russia Seeks to Distribute its Accelerated Gamaleya Vaccine to the Philippines (2020). Available online at: (accessed August 20, 2020).
    1. Russia to Begin COVID-19 Vaccine Trials on 40 000 People Next Week Reuters. (2020). Available online at: (accessed August 26, 2020).
    1. Thomas SJ, Yoon IK. A review of Dengvaxia®: development to deployment. Hum Vaccin Immunother. (2019) 15:2295–314. 10.1080/21645515.2019.1658503
    1. Jamrozik E, Selgelid MJ. COVID-19 human challenge studies: ethical issues. Lancet Infect Dis. (2020) 20:198–203. 10.1007/978-3-030-41480-1
    1. Harlan C, Pitrelli S. From Oxford to an Italian Lab, One Race for Coronavirus Vaccine is gaining Backers. (2020). Available online at: (accessed June 27, 2020).
    1. Liu Y, Salwi S, Drolet B. Multivalue ethical framework for fair global allocation of a COVID-19 vaccine. J Med Ethics. (2020) 46:499–501. 10.1136/medethics-2020-106516
    1. Makhoul M, Ayoub HH, Chemaitelly H, Seedat S, Mumtaz GR, Al-Omari S, et al. Epidemiological impact of SARS-CoV-2 vaccination: mathematical modeling analyses. medRxiv [Preprint]. (2020). 10.1101/2020.04.19.20070805
    1. Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, et al. Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2. bioRxiv [Preprint]. (2020). 10.1101/2020.04.29.069054
    1. Grubaugh ND, Hanage WP, Rasmussen AL. Making sense of mutation: what D614G means for the COVID-19 pandemic remains unclear. Cell. (2020) 182:794–5. 10.1016/j.cell.2020.06.040
    1. Morris KV. The improbability of the rapid development of a vaccine for SARS-CoV-2. Mol Ther. (2020) 28:1548–49. 10.1016/j.ymthe.2020.06.005
    1. Garber K. Coronavirus Vaccine Developers Wary of Errant Antibodies. (2020). Available online at: (accessed August 20, 2020).
    1. Thanh Le T, Andreadakis Z, Kumar A, Gomez Roman R, Tollefsen S, Saville M, et al. . The COVID-19 vaccine development landscape. Nat Rev Drug Discov. (2020) 19:305–6. 10.1038/d41573-020-00073-5
    1. Gabbatt A. US Anti-Vaxxers Aim to Spread Fear Over Future Coronavirus Vaccine. (2020). Available online at: (accessed June 26, 2020).
    1. Neergaard L, Fingerhut H. AP-NORC Poll: Half of Americans would get a COVID-19 Vaccine. (2020). Available online at: (accessed July 10, 2020).
    1. Barach P, Fisher SD, Adams MJ, Burstein GR, Brophy PD, Kuo DZ, et al. . Disruption of healthcare: Will the COVID pandemic worsen non-COVID outcomes and disease outbreaks? Prog Pediatr Cardiol. (2020) 2020:101254. 10.1016/j.ppedcard.2020.101254
    1. Mello MM, Silverman RD, Omer SB. Ensuring uptake of vaccines against SARS-CoV-2. (2020). 10.1056/NEJMp2020926. [Epub ahead of print].
    1. Span P. Older Adults May Be Left Out Of Some COVID-19 Trials. (2020). Available online at: (accessed July 6, 2020).
    1. Gothelf A, Gehl J. What you always needed to know about electroporation based DNA vaccines. Hum Vaccin Immunother. (2012) 8:1694–702. 10.4161/hv.22062
    1. Global Vaccine Summit 2020 (2020). Available online at: (accessed July 6, 2020).
    1. Deming ME, Michael NL, Robb M, Cohen MS, Neuzil KM. Accelerating development of SARS-CoV-2 vaccines — the role for controlled human infection models. N Engl J Med. (2020) 383:e63. 10.1056/NEJMp2020076
    1. Malik YS, Kumar N, Sircar S, Kaushik R, Bhat S, Dhama K, et al. . Coronavirus disease pandemic (COVID-19): challenges and a global perspective. Pathogens. (2020) 9:519. 10.3390/pathogens9070519
    1. Dai L, Zheng T, Xu K, Han Y, Xu L, Huang E, et al. . A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS. Cell. (2020) 182:722–33.e11. 10.1016/j.cell.2020.06.035

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다